Program Code: SCF-CMM-CICADA-0001
Framework: SCF Viragenesis + Multi-Omic Structural Evolution + Resistance Modeling
SECTION I — SCOPE & MODEL DESIGN
1.1 Objective
To construct a residue-level mutation map for:
- Spike Glycoprotein (S) → Host entry, immune escape
- RNA-dependent RNA polymerase (RdRp / NSP12) → Replication fidelity, mutation rate
1.2 Computational Layers
Layer | Function |
Structural Modeling | 3D conformational drift |
Mutation Probability Matrix | Residue-level mutation likelihood |
Fitness Landscape | Viral replication vs immune escape |
SCF Alignment | Resistance + safety + PK optimization |
SECTION II — SPIKE PROTEIN MUTATION MAP (S1 + S2)
2.1 Functional Domains
Domain | Residue Range | Function |
NTD | 14–305 | Immune recognition |
RBD | 319–541 | ACE2 binding |
RBM | 438–506 | Direct receptor interface |
Furin Cleavage Site | 681–686 | Activation |
S2 Fusion Core | 816–1213 | Membrane fusion |
2.2 HIGH-PROBABILITY MUTATION HOTSPOTS (CICADA MODEL)
A. RBD / RBM (Immune Escape Core)
Residue | Mutation | Functional Impact |
K417 | K417N/T | Antibody escape |
L452 | L452R/Q | Increased infectivity |
T478 | T478K | Electrostatic binding ↑ |
E484 | E484K/A | Major immune escape |
N501 | N501Y | ACE2 affinity ↑ |
Q498 | Q498R | Synergistic binding with N501Y |
B. NTD (Antigenic Supersite Drift)
Region | Mutation Pattern | Effect |
Δ69–70 | Deletion | Immune evasion |
Δ144 | Deletion | Antibody escape |
NTD loops | Insertions/deletions | Antigenic masking |
C. FURIN CLEAVAGE REGION
Residue | Mutation | Effect |
P681 | P681R/H | Increased cleavage efficiency |
H655 | H655Y | Fusion enhancement |
D. S2 FUSION CORE
Residue | Mutation | Effect |
D950 | D950N | Fusion stability |
S982 | S982A | Structural flexibility |
2.3 CICADA-SPECIFIC EVOLUTION PATTERN
Predicted Pattern:
- Cyclic emergence of:
- RBD hypermutation clusters
- NTD deletions
- Furin cleavage optimization
→ Produces wave-based infectivity spikes
SECTION III — RdRp (NSP12) MUTATION MAP
3.1 Functional Domains
Domain | Residue Range | Function |
NiRAN domain | 1–250 | Nucleotide transfer |
Interface domain | 250–365 | Cofactor binding |
Polymerase domain | 366–920 | RNA synthesis |
3.2 HIGH-PROBABILITY RdRp MUTATIONS
Residue | Mutation | Functional Impact |
P323 | P323L | Stability ↑, global dominant |
G671 | G671S | Replication efficiency ↑ |
V720 | V720I | Polymerase flexibility |
D618 | D618G | Catalytic alteration |
E802 | E802D | Antiviral resistance risk |
3.3 MUTATION EFFECT CLUSTERS
Cluster | Effect |
Fidelity Reduction | Higher mutation rate |
Replication Acceleration | Faster viral load growth |
Drug Resistance | Reduced antiviral binding |
SECTION IV — SPIKE–RdRp CO-EVOLUTION MATRIX
Interaction | Outcome |
Spike ↑ binding + RdRp ↑ replication | Hypertransmissibility |
Spike immune escape + RdRp fidelity ↓ | Rapid variant emergence |
RdRp resistance + Spike drift | Antiviral + vaccine escape |
SECTION V — MUTATION PROBABILITY HEATMAP (SCF MODEL)
Region | Mutation Probability | Risk Level |
RBD (438–506) | Very High | Critical |
NTD loops | High | High |
Furin site | High | High |
S2 core | Moderate | Medium |
RdRp active site | Moderate–High | Critical |
SECTION VI — FITNESS LANDSCAPE MODEL
6.1 Fitness Axes
Axis | Description |
Infectivity | ACE2 binding efficiency |
Immune Escape | Antibody evasion |
Replication Rate | RNA synthesis speed |
Stability | Structural integrity |
6.2 CICADA VARIANT OPTIMAL ZONE
- High infectivity
- Moderate immune escape
- High replication speed
- Maintained structural stability
SECTION VII — RESISTANCE MODELING (SCF PRINCIPLES)
Aligned with resistance prevention
7.1 Risk
- Single-target antivirals → rapid resistance via RdRp mutation
- Spike-target vaccines → escape via RBD drift
7.2 SCF SOLUTION
Strategy | Target |
Dual-target inhibition | Spike + RdRp |
Multi-pathway targeting | Immune + metabolic |
High-barrier design | Multi-residue binding |
SECTION VIII — SCF THERAPEUTIC TARGET MAP
Target | Residue Cluster | Strategy |
Spike RBD | 417–501 | Neutralizing antibodies / small molecules |
Furin site | 681–686 | Cleavage inhibitors |
RdRp active site | 600–800 | Nucleoside analogs |
RdRp interface | 250–365 | Allosteric inhibitors |
SECTION IX — PREDICTIVE MUTATION TRAJECTORY (CICADA MODEL)
Phase-Based Evolution
Phase | Mutation Pattern |
T1 | RdRp mutation → replication increase |
T2 | Spike RBD mutation → immune escape |
T3 | NTD deletions → antigenic masking |
T4 | Furin optimization → infectivity spike |
T5 | Stabilizing mutations → variant dominance |
SECTION X — TRANSLATIONAL IMPLICATIONS
10.1 Drug Development
- Target conserved residues in RdRp
- Avoid single epitope Spike targeting
10.2 Vaccine Design
- Multi-epitope vaccines
- Include conserved S2 regions
10.3 Clinical Strategy
- Early antiviral combination therapy
- Biomarker-guided intervention
SECTION XI — INTEGRATED SCF SUMMARY
The Cicada Variant mutation system is characterized by:
- RBD hypermutation cycles
- RdRp-driven mutation acceleration
- Spike–polymerase co-evolution
- High resistance potential
Optimal countermeasure:
→ SCF multi-target therapeutic architecture with adaptive evolution tracking
MASTER REGISTRY INDEX
- SCF-CMM-CICADA-0001
- SCF-VIR-CICADA-0001
- SCF-MPC-CVR-0001
- SCF-PATHO-EXT-0001
- SCF-SEF-MD-0001
- SCF-SCP-PRINCIPLES-0001
Next Step Options
- SCF Drug Candidate Design (SMILES + docking-ready scaffold)
- AI mutation simulation matrix (10,000 variant projections)
- IND-ready antiviral combination therapy blueprint